Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020)

Helio S Sader; Mariana Castanheira; Leonard R Duncan; Rodrigo E Mendes

doi:10.1016/j.diagmicrobio.2022.115820

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020)

Diagn Microbiol Infect Dis. 2023 Jan;105(1):115820. doi: 10.1016/j.diagmicrobio.2022.115820. Epub 2022 Sep 23.

Authors

Helio S Sader¹, Mariana Castanheira², Leonard R Duncan², Rodrigo E Mendes²

Affiliations

¹ JMI Laboratories, North Liberty, Iowa, USA. Electronic address: helio-sader@jmilabs.com.
² JMI Laboratories, North Liberty, Iowa, USA.

PMID: 36274343
DOI: 10.1016/j.diagmicrobio.2022.115820

Abstract

Ceftaroline and comparators were tested against 9,268 Staphylococcus aureus isolates from 33 United States hospitals (2018-2020). Ceftaroline (MIC_50/90, 0.25/1 mg/L) susceptibility ranged from 95.4% (pneumonia) to 98.5% (skin and skin structure) and was 97.2% overall. Ceftaroline retained potent and broad-spectrum activity against methicillin-resistant isolates, with a 93.4% overall susceptibility.

Keywords: MRSA; Staphylococcus aureus; ceftaroline; pneumonia; skin and skin structure infection.

MeSH terms

Anti-Bacterial Agents / pharmacology
Ceftaroline
Cephalosporins / pharmacology
Hospitals
Humans
Methicillin-Resistant Staphylococcus aureus*
Microbial Sensitivity Tests
Staphylococcal Infections* / epidemiology
Staphylococcus aureus
United States

Substances

Anti-Bacterial Agents
Cephalosporins